Clinical trial designs for the early clinical development of therapeutic cancer vaccines.
暂无分享,去创建一个
S. Steinberg | J. Berzofsky | R. Simon | A. Hildesheim | J. Schlom | S. Topalian | L. Kwak | C. Mackall | S. Khleif | S M Steinberg | J A Berzofsky | J Schlom | S L Topalian | L W Kwak | C L Mackall | A Hildesheim | R M Simon | M Hamilton | S Khleif | M. Hamilton
[1] R Simon,et al. Investigating a sequence of randomized phase II trials to discover promising treatments. , 1995, Statistics in medicine.
[2] J Whitehead,et al. Designing phase II studies in the context of a programme of clinical research. , 1985, Biometrics.
[3] J. Cormier,et al. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. , 1996, Cancer research.
[4] R Simon,et al. Bayesian design and analysis of two x two factorial clinical trials. , 1997, Biometrics.
[5] S S Ellenberg,et al. Randomized phase II clinical trials. , 1985, Cancer treatment reports.
[6] Craig W. Reynolds,et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte–monocyte colony-stimulating factor against lymphoma , 1999, Nature Medicine.
[7] T J Yao,et al. Optimal two-stage design for a series of pilot trials of new agents. , 1998, Biometrics.
[8] F. Marincola,et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. , 1997, The cancer journal from Scientific American.
[9] Richard Simon,et al. A Bayesian approach to establishang sample size and monitoring criteria for phase II clinical trials , 1994 .
[10] C B Begg,et al. Optimal sample size for a series of pilot trials of new agents. , 1996, Biometrics.
[11] R W Makuch,et al. Sample size considerations for non-randomized comparative studies. , 1980, Journal of chronic diseases.
[12] P. Thall,et al. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. , 1995, Statistics in medicine.
[13] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[14] R Simon,et al. Sample size considerations for studies comparing survival curves using historical controls. , 1988, Journal of clinical epidemiology.
[15] F. Marincola,et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.